{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000020","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.245216+00:00","generated_at":"2026-05-23T09:12:12.099004+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iBio licenses first-in-class anti-Activin E antibody from AstralBio for up to $28M in milestones","bullets":["Upfront $750K credit applied toward option fee; total milestone payments up to $28M, payable in cash or stock.","Antibody demonstrated fat-selective weight loss and synergy with GLP-1 in obese rodent model.","iBio also amended AstralBio collaboration to add a fifth cardiometabolic target using its AI platform.","AstralBio eligible for low to mid-single-digit sublicense fees on any sublicense proceeds.","iBio solely responsible for all development, manufacturing, and commercialization worldwide."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000020","json":"https://secwatch.observer/filing/0001420720-25-000020.json","markdown":"https://secwatch.observer/filing/0001420720-25-000020.md","text":"https://secwatch.observer/filing/0001420720-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000020/0001420720-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000020/ibio-20250421x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T09:12:12.099004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}